The stock market, fundraising and milestones
- Kurma Biofund completes its first two investments
- ThromboGenics raises EUR 56 m
- EUR 15.5 m for SuppreMol
- New investor for Covagen
- First Ablynx molecule selected by Boehringer Ingelheim
- Staggered payment for Symphogen under its agreement with Genentech
Clinical trials
- Initial victory for Néovacs Kinoids
- A conclusive phase III study for Amarin's Omega-3
- End of the line for second Intercell vaccine